



GlaxoSmithKline Consumer
Healthcare Pakistan Limited
35-Dockyard Road,
West Wharf,
Karachi - 74000,
Pakistan

UAN +92 21 111 475 725
Fax +92 21 3220 1855
www.gsk.com.pk

May 21, 2020

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi - 74000

Subject: Financial Results for the Quarter Ended March 31, 2020

Dear Sir,

This is to inform you that the Board of Directors of our company in their meeting held on May 20, 2020, at GSK Consumer Healthcare Pakistan Limited, 35-Dockyard Road, West Wharf, Karachi, recommended the following:

(i) **CASH DIVIDEND**

Nil

AND/OR

(ii) **BONUS SHARES**

NIL

The financial results of the Company are as follows:

	March 31, 2020	March 31, 2019
Revenue from contracts with customers	4,308,054,833	3,870,909,955
Cost of sales	(2,903,678,819)	(2,775,762,996)
Gross profit	1,404,376,014	1,095,146,959
Selling, marketing and distribution expenses	(872,916,471)	(720,240,746)
Administrative expenses	(65,210,967)	(71,522,713)
Other operating expenses	(34,942,188)	(22,449,200)
Other income	7,454,355	12,963,706
Operating profit	438,760,743	293,898,006
Financial charges	(21,405,568)	(38,135,246)



Profit before taxation	417,355,175	255,762,760
Taxation	(116,693,901)	(88,448,076)
Profit after taxation	300,661,274	167,314,684
Other comprehensive loss		
Items that will not be reclassified to profit or loss:		
Remeasurement of staff retirement benefits	-	-
Impact of deferred tax	-	-
Other comprehensive loss for the year	-	-
Total comprehensive income	300,661,274	167,314,684
Earnings per share – Rs	2.57	1.43

Yours Sincerely,


Mehar-e-Daraksha
Company Secretary

cc: Head of Operation,
Central Depository Company of Pakistan Limited,
99-B, Block – B, S.M.C.H.S.,
Main Shahra-e-Faisal,
Karachi – 74000

Director/HOD,
Surveillance, Supervision and Enforcement Department
Securities and Exchange Commission of Pakistan
NIC Building, 63 Jinnah Avenue,
Blue Area,
Islamabad.